硫酸乙酰肝素蛋白多糖基因多态性与草酸钙结石易感性的关系
|
摘要
目的
1.探讨硫酸乙酰肝素蛋白多糖(HSPG)基因rs3767140位点多态性与中国汉族人群草酸钙肾结石易感性的关系。
2.分析硫酸乙酰肝素蛋白多糖(HSPG)基因rs3767140位点多态性与中国汉族人群草酸钙肾结石复发的相关性。方法
以病例对照研究方法,提取143例草酸钙肾结石患者及157例健康对照者外周血标本基因组DNA,应用聚合酶链反应一限制性片断长度多态性(PCR-RFLP)分析技术,检测并分析HSPG基因rs3767140位点单核甘酸多态性与草酸钙肾结石形成及复发的关系。记录并比较两组间年龄、性别构成比、体重、身高和身体质量指数之间的差异。统计学处理使用SPSS13.0软件完成,组间计量资料以均数±标准差((?)±s)表示,计量资料比较使用t检验,计数资料比较采用χ2检验,使用非条件Logistic回归进行多因素分析计算各基因型与草酸钙尿路结石复发的关联强度。结果
健康对照组与结石组临床资料比较：两组间年龄、性别构成比、体重、身高和身体质量指数之间的差异无统计学意义(P>0.05)；HSPG基因等位基因频率分布符合Hardy-Weinberg平衡定律(结石组χ2=0.094,P>0.05；对照组χ2=0.107,P>0.05),具有群体代表性；结石组GG+GT、TT基因型分布频率分别为69.23％、30.77％,健康对照组分别为79.62％、20.38％,差异有统计学意义(P<0.05),TT基因型个体患结石的风险是其它基因型的1.736倍(OR=1.736,95％CI=1.026～2.938),结石组与对照组等位基因G、T分布频率分别为：45.10％、55.90％和54.14％、45.86％(P<0.05)；未发现HSPG基因多态性与草酸钙结石的复发相关。
结论
1.山东汉族健康人群中存在HSPG基因rs3767140位点单核苷酸多态性。G等位基因在健康人群中的分布频率大约为54.14％。
2.HSPG基因rs3767140位点多态性与草酸钙肾结石发生有相关关系。TT基因型可作为草酸钙结石危险因素的标志。TT基因型个体患结石的风险是其它基因型的1.736倍。
3.等位基因G可能是结石形成的保护因素。
4.HSPG基因rs3767140位点多态性可能与草酸钙尿路结石复发无相关关系。
Objective:
1.To explore the potential association between the Heparan Sulfate Proteoglycan gene polymorphism and genetic susceptibility to calcium oxalate nephrolithiasis in Chinese Han population.
2.To investigate correlation of the Heparan Sulfate Proteoglycan gene polymorphism with calcium oxalate stone recurrence.
Methods:
In this study,totally 143 patients diagnosed with calcium oxalate urolithiasis were studied.In addition,157 age-matched healthy controls were enrolled.Genomic DNA were extracted from blood samples.Based on case-control study,Heparan Sulfate Proteogylcan gene polymorphism (rs3767140) was determined by polymerase chain reaction and restriction fraction length polymorphism(PCR-RFLP) with BamH I digestion.The correlation of the heparan sulfate proteoglycan gene polymorphism with calcium oxalate stone and calcium oxalate stone recurrence was investigated.Meanwhile age,sex composition,weight,height and body mass index (BMI) were analyzed.All statistical tests were carried out by the SPSS 13.0 software.The associations of clinical features,including age,weight,hight and body mass index (BMI), were tested using T test.Measurement date interclass was indicated with x±s.The differences in sex composition and genotype frequencies between the cases and controls were tested using x2-test. Unconditional logistic regression model was used to assess the association between correlative factors and calcium oxalate stone recurrence.
Results:
Differences of age,sex composition,weight,height and body mass index (BMI) between the two groups were not significant(P>0.05).The distribution frequencies of site rs3767140 genotype and alleles in the two groups followed the Hardy-Weinberg equilibrium(P> 0.05).The distribution frequencies of the GG+GT,TT genotypes were 69.23%,30.77% in oxalate calcium urolithiasis group and 79.62%,20.38% respectively in healthy control group.The differences between the two groups were statistically significant(P<0.05).The distribution frequencies of G and T alleles in stone and control groups were 45.10%,55.90% and 54.14%,45.86% respectively,and statistical differences were observed(P<0.05).The subjects with TT genotype yielded a 1.736 fold increased risk for calcium oxalate nephrolithiasis,compared with subjects with GT+GG genotype(OR=1.736,95%CI=1.026～2.938),however,we did not find the association between HSPG gene polymorphism and the possibility of stone recurrence.
Conclusions:
1.There are G/T polymorphisms in HSPG gene in Chinese Han population of Shandong Province.The allele G frequency in healthy control is about 54.14%.
2.There is significant association between HSPG gene polymorphism and calcium oxalate nephrolithiasis. The TT genotype may be a good genetic marker for calcium oxalate nephrolithiasis.The subjects with TT genotype yielded a 1.736 fold increased risk for calcium oxalate nephrolithiasis,compared with subjects with GT+GG genotypes.
3.Allele G may be a protective factor for calcium oxalate nephrolithiasis..
4.There is no significant association between HSPG gene polymorphism and calcium oxalate stone recurrence.
1.探讨硫酸乙酰肝素蛋白多糖(HSPG)基因rs3767140位点多态性与中国汉族人群草酸钙肾结石易感性的关系。
2.分析硫酸乙酰肝素蛋白多糖(HSPG)基因rs3767140位点多态性与中国汉族人群草酸钙肾结石复发的相关性。方法
以病例对照研究方法,提取143例草酸钙肾结石患者及157例健康对照者外周血标本基因组DNA,应用聚合酶链反应一限制性片断长度多态性(PCR-RFLP)分析技术,检测并分析HSPG基因rs3767140位点单核甘酸多态性与草酸钙肾结石形成及复发的关系。记录并比较两组间年龄、性别构成比、体重、身高和身体质量指数之间的差异。统计学处理使用SPSS13.0软件完成,组间计量资料以均数±标准差((?)±s)表示,计量资料比较使用t检验,计数资料比较采用χ2检验,使用非条件Logistic回归进行多因素分析计算各基因型与草酸钙尿路结石复发的关联强度。结果
健康对照组与结石组临床资料比较：两组间年龄、性别构成比、体重、身高和身体质量指数之间的差异无统计学意义(P>0.05)；HSPG基因等位基因频率分布符合Hardy-Weinberg平衡定律(结石组χ2=0.094,P>0.05；对照组χ2=0.107,P>0.05),具有群体代表性；结石组GG+GT、TT基因型分布频率分别为69.23％、30.77％,健康对照组分别为79.62％、20.38％,差异有统计学意义(P<0.05),TT基因型个体患结石的风险是其它基因型的1.736倍(OR=1.736,95％CI=1.026～2.938),结石组与对照组等位基因G、T分布频率分别为：45.10％、55.90％和54.14％、45.86％(P<0.05)；未发现HSPG基因多态性与草酸钙结石的复发相关。
结论
1.山东汉族健康人群中存在HSPG基因rs3767140位点单核苷酸多态性。G等位基因在健康人群中的分布频率大约为54.14％。
2.HSPG基因rs3767140位点多态性与草酸钙肾结石发生有相关关系。TT基因型可作为草酸钙结石危险因素的标志。TT基因型个体患结石的风险是其它基因型的1.736倍。
3.等位基因G可能是结石形成的保护因素。
4.HSPG基因rs3767140位点多态性可能与草酸钙尿路结石复发无相关关系。
Objective:
1.To explore the potential association between the Heparan Sulfate Proteoglycan gene polymorphism and genetic susceptibility to calcium oxalate nephrolithiasis in Chinese Han population.
2.To investigate correlation of the Heparan Sulfate Proteoglycan gene polymorphism with calcium oxalate stone recurrence.
Methods:
In this study,totally 143 patients diagnosed with calcium oxalate urolithiasis were studied.In addition,157 age-matched healthy controls were enrolled.Genomic DNA were extracted from blood samples.Based on case-control study,Heparan Sulfate Proteogylcan gene polymorphism (rs3767140) was determined by polymerase chain reaction and restriction fraction length polymorphism(PCR-RFLP) with BamH I digestion.The correlation of the heparan sulfate proteoglycan gene polymorphism with calcium oxalate stone and calcium oxalate stone recurrence was investigated.Meanwhile age,sex composition,weight,height and body mass index (BMI) were analyzed.All statistical tests were carried out by the SPSS 13.0 software.The associations of clinical features,including age,weight,hight and body mass index (BMI), were tested using T test.Measurement date interclass was indicated with x±s.The differences in sex composition and genotype frequencies between the cases and controls were tested using x2-test. Unconditional logistic regression model was used to assess the association between correlative factors and calcium oxalate stone recurrence.
Results:
Differences of age,sex composition,weight,height and body mass index (BMI) between the two groups were not significant(P>0.05).The distribution frequencies of site rs3767140 genotype and alleles in the two groups followed the Hardy-Weinberg equilibrium(P> 0.05).The distribution frequencies of the GG+GT,TT genotypes were 69.23%,30.77% in oxalate calcium urolithiasis group and 79.62%,20.38% respectively in healthy control group.The differences between the two groups were statistically significant(P<0.05).The distribution frequencies of G and T alleles in stone and control groups were 45.10%,55.90% and 54.14%,45.86% respectively,and statistical differences were observed(P<0.05).The subjects with TT genotype yielded a 1.736 fold increased risk for calcium oxalate nephrolithiasis,compared with subjects with GT+GG genotype(OR=1.736,95%CI=1.026～2.938),however,we did not find the association between HSPG gene polymorphism and the possibility of stone recurrence.
Conclusions:
1.There are G/T polymorphisms in HSPG gene in Chinese Han population of Shandong Province.The allele G frequency in healthy control is about 54.14%.
2.There is significant association between HSPG gene polymorphism and calcium oxalate nephrolithiasis. The TT genotype may be a good genetic marker for calcium oxalate nephrolithiasis.The subjects with TT genotype yielded a 1.736 fold increased risk for calcium oxalate nephrolithiasis,compared with subjects with GT+GG genotypes.
3.Allele G may be a protective factor for calcium oxalate nephrolithiasis..
4.There is no significant association between HSPG gene polymorphism and calcium oxalate stone recurrence.
引文
[1]TISELIYS HGStone insidence and prevention[J].Braz J Urol,2000,26(5):452-462.
[2]TISELIUS HGEpidemiology and medical management of stone disease[J]. BJU Int,2003,91(8):758-767.
[3]孙伟桂,丁智仁,张峻,等.广西的区尿石症患者年龄分布曲线特征及临床意义[J].中华泌尿外科杂志,2001,22(2)：100-102.
[4]欧阳健明.草酸钙结石研究中的化学基础[J].化学通报,2002(5)：326-332.
[5]Uribarri J, Oh MS, Carroll HJ. The first kidney stone[J]. Annals of internal medicine,1989,111(12):1006-9.
[6]Coe FL, Parks JH, Asplin JR.The pathogenesis and treatment of kidney stones [J]. The New England journal of medicine,1992,327(16):1141-52.
[7]陈孝平,主编.外科学[M].北京：人民卫生出版社,2005.858.
[8]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.54-55.
[9]Kumar V, Lieske JC. Protein regulation of intrarenal crystallization[J]. Current Opinionin nephrology and hypertension,2006,15(4):374-80.
[10]De Yoreo JJ, Qiu SR, Hoyer JR.Molecular modulation of calcium oxalate crystal lization[J].American journal of physiology.Renal physiology,2006,291 (6):1123-31.
[11]Filmus J, Selleck SB.Glypicans:proteoglycans with a surprise[J]. The Journal of clinical investigation,2001,108(4):497-501.
[12]Iozzo RV.Heparan sulfate proteoglycans:intricate molecules with intriguing functions[J]. The Journal of clinical investigation,2001,108(2):165-7.
[13]Groffen AJ, Veerkamp JH, Monnens LA, et al.Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane[J]. Nephrology, dialysis, transplantation,1999,14(9):2119-29.
[14]Iwata H, Terado T, Kin M, et al.Isolation of urinary heparan sulfate and chondroitin sulfate and their inhibitory activity of calcium oxalate crystal growth[J]. The Japanese Journal of Urology,1991,82(3):405-11.
[15]Iida S, Miyajima J, Suzuki K, et al. Expression of heparan sulfate proteoglycan mRNA in rat kidneys during calcium oxalate nephrolithiasis[J]. Urological research, 1997,25(5):361-4.
[16]Iida S, Inoue M, Yoshii S, et al. Molecular detection of heparan sulfate proteogly can mRNA in rat kidney during calcium oxalate nephrolithiasis[J] Journal of the American Society of Nephrology,1999,10 Suppl14:S412-6.
[17]Eguchi Y, Inoue M, Iida S, et al. Heparan sulfate (HS)/heparan sulfate proteogly can (HSPG) and bikunin are up-regulated during calcium oxalate nephrolithiasis in rat kidney[J]. The Kurume medical journal,2002,49(3):99-107.
[18]Matsuo M. Increased expression of heparan sulfate proteoglycan on the cultured renal epithelial cells during oxalate exposure[J]. The Kurume medical journal,2008, 55(1-2):19-28.
[19]Chikama S, Iida S, Inoue M, et al.Role of heparan sulfate proteoglycan (syndecan-1) on the renal epithelial cells during calcium oxalate monohydrate crystal attachment[J]. The Kurume medical journal,2002,49(4):201-10.
[20]Angell AH, Resnick MI.Surface interaction between glycosaminoglycans and calcium oxalate[J]. The Journal of urology,1989,141(5):1255-8.
[21]Hansen PM, Chowdhury T, Deckert T,et al.Genetic variation of the heparin sulfate proteoglycan gene (perlecan gene). Association with urinary albumin excretion in IDDM patients[J]. Diabetes,1997,46(10):1658-9.
[22]Liu L, Xiang K, Zheng T, et al.The heparan sulfate proteoglycan gene polymor phism:association with type 2 diabetic nephropathy in Chinese[J]. Molecular and cellular biochemistry,2003,245(1-2):121-6.
[23]Onaran M, Yilmaz A, Sen I, et al.Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis[J].Urological research,2009,37(l):47-50.
[24]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.301.
[25]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.215.
[26]Winter P, Schoeneich G, Ganter K, et al.Extracorporeal shock wave lithotripsy and glycosaminoglycans in urine[J].International urology and nephrology,1998, 30(2):113-21.
[27]Garside RF. Bimodality and the nature of depression[J].The British journal of psychiatry:the journal of mental science,1981,139:168-9.
[28]Khan SR. Role of renal epithelial cells in the initiation of calcium oxalate stones [J].Nephron. Experimental nephrology,2004,98(2):55-60.
[29]Khan SR, Kok DJ. Modulators of urinary stone formation[J]. Frontiers in bio science,2004,9:1450-82.
[30]Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans[J]. Annual review of biomedical engineering,2006,8:181-231.
[31]Borges FT, Michelacci YM, Aguiar JA, et al.Characterization of glycosaminogly cans in tubular epithelial cells:calcium oxalate and oxalate ions effects[J]. Kidney international,2005,68(4):1630-42.
[32]Rosenmann H, Meiner Z, Kahana E, et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease[J]. American journal of medical genetics,2004,128B(1):123-5.
[33]Iivonen S, Helisalmi S, Mannermaa A, et al. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology[J]. Neuroscience letters,2003,352(2):146-50.
[34]Datta MW, Hernandez AM, Schlicht MJ, et al. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway [J].Molecular cancer,2006,5:9.
[35]李大伟,焦伟,王铁柳,等.硫酸乙酰肝素蛋白多糖基因多态性与草酸钙结石易感性的关系.山东大学学报.2010,48(1)：89-94.
[36]Minamitani K, Takahashi Y, Minagawa M, et al. Difference in height associated with a translation start site polymorphism in the vitamin D receptor gene[J]. Pediatric research,1998,44(5):628-32.
[37]Ferrari S, Rizzoli R, Manen D, et al.Vitamin D receptor gene start codon polymer phisms(Fokl) and bone mineral density:interaction with age, dietary calcium, and 3'-end region polymorphisms[J].Journal of bone and mineral research,1998,13(6): 925-30.
[38]董砚虎,翟木绪,李长贵,等.糖尿病维生素D受体基因多态性与骨密度相 关性研究[J].中华内分泌代谢杂志,2002,18(2)：111-115.
[39]易广才,邵振堂,阮滨.维生素D受体基因内切酶位点多态与孕妇骨密度和补钙的关系[J].中国优生与遗传杂志,2002,10(2)：111-115.
[40]Ozkaya O, Soylemezoglu O, Misirlioglu M, et al. Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children[J].European urology,2003,44(1):150-4.
[41]Nishijima S, Sugaya K, Naito A, et al. Association of vitamin D receptor gene polymorphism with urolithiasis[J].The Journal of urology,2002,167(5):2188-91.
[42]Gunes S, Bilen CY, Kara N, et al. Vitamin D receptor gene polymorphisms in patients with urolithiasis[J].Urological research,2006,34(1):47-52.
[43]Jackman SV, Kibel AS, Ovuworie CA, et al. Familial calcium stone disease:TaqI polymorphism and the vitamin D receptor[J] Journal of endourology,1999,13(4): 313-6.
[44]Heilberg IP, Teixeira SH, Martini LA, et al.Vitamin D receptor gene polymorphism and bone mineral density in hypercalciuric calcium-stone-forming patients[J].Nephron,2002,90(1):51-7.
[45]Bid HK,Chaudhary H, Mittal RD.Association of vitamin-D and calcitonin receptor gene polymorphism in paediatric nephrolithiasis[J]. Pediatric nephrology (Berlin, Germany),2005,20(6):773-6.
[46]Chen WC, Chen HY, Lu HF, et al. Association of the vitamin D receptor gene start codon Fok I polymorphism with calcium oxalate stone disease[J].BJU international,2001,87(3):168-71.
[47]胡少群,刘继红,王少刚,等.维生素D受体基因多态性与草酸钙尿结石的关系[J].中华泌尿外科杂志,2004,25(3)：155-157.
[48]王勤章,钱彪,丁国富,等.新疆南部维吾尔族泌尿系结石患者维生素D受体基因多态性的研究[J].实用医学杂志,2009,25(17)：2805-2807.
[49]梁颖,刘忠厚.遗传决定骨量[J].中国骨质疏松杂志,2005,11(2)：269-272.
[50]苗懿德,刘杰,何培英,等.老年男性维生素D受体基因多态性与骨转换指 标及1,25(OH)2D3的关系[J].中国临床康复,2004,8(33)：7469-7471.
[51]Urivetzky M, Anna PS, Smith AD. Plasma osteocalcin levels in stone disease. A potential aid in the differential diagnosis of calcium nephrolithiasis[J]. The Journal of urology,1988,139(1):12-4.
[52]Yasui T, Fujita K, Sasaki S, et al. Expression of bone matrix proteins in urolithiasis model rats[J].Urological research,1999,27(4):255-61.
[53]McKee MD, Nanci A, Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi[J]. Journal of bone and mineral research,1995,10(12):1913-29.
[54]Worcester EM, Sebastian JL, Hiatt JG, et al. The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin[J] Calcified tissue international,1993,53(4):242-8.
[55]Dohi Y, Iki M, Ohgushi H, et al. A novel polymorphism in the promoter region for the human osteocalcin gene:the possibility of a correlation with bone mineral density in postmenopausal Japanese women[J] Journal of bone and mineral research,1998,13(10):1633-9.
[56]Celeste AJ, Rosen V, Buecker JL, et al. Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones[J].The EMBO journal,1986,5 (8): 1885-90.
[57]Raymond MH, Schutte BC, Torner JC, et al. Osteocalcin:genetic and physical mapping of the human gene BGLAP and its potential role in postmenopausal osteoporosis[J].Genomics,1999,60(2):210-7.
[58]Morrison N, Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter[J]. Journal of bone and mineral research,1993,8(8):969-75.
[59]Mo XY, Cao CK, Xu FH, et al. Lack of association between the HindⅢ RFLP of the osteocalcin (BGP) gene and bone mineral density (BMD) in healthy pre-and postmenopausal Chinese women[J]. Journal of bone and mineral metabolism,2004, 22(3):264-9.
[60]吴青,张红红,刘建伟,等.汉族人骨钙素基因多态性和骨质疏松的关系[J].中国临床康复,2004,8(30)：6806-6807.
[61]Chen WC, Chen HY, Wu JY, et al. Osteocalcin gene Hind Ⅲ polymorphism is not correlated with calcium oxalate stone disease[J]. Urological research,2001,29(2): 98-101.
[62]Tawada T, Fujita K, Sakakura T, et al. Distribution of osteopontin and calprotectin as matrix protein in calcium-containing stone[J]. Urological research,1999,27(4): 238-42.
[63]Shiraga H, Min W, VanDusen WJ, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin:another member of the aspartic acid-rich protein superfamily[J]. Proceedings of the National Academy of Sciences of the United States of America,1992,89(1):426-30.
[64]常连胜,冯陶,郭应禄,等.结石病人尿骨桥蛋白测定的临床意义.中华泌尿外科杂志.2000,21(12)：709-711.
[65]Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals [J].Kidney international,2001,60(1):77-82.
[66]Butler WT. The nature and significance of osteopontin[J]. Connective tissue research,1989,23(2-3):123-36.
[67]Gao B, Yasui T, Okada A, et al. A polymorphism of the osteopontin gene is related to urinary calcium stones[J].The Journal of urology,2005,174(l):1472-6.
[68]Kikuchi K, Tanaka A, Miyakawa H, et al.Eta-1/osteopontin genetic polymor phism and primary biliary cirrhosis[J].Hepatology research,2003,26(2):87-90.
[69]Lee M.K,Kim T.H,Lee S.Y,et al. ETA-1/OSTEOPONTIN GENETIC POLYMORPHISIMS ASSOCIATED WITH UROLITHIASIS IN KOREA[J]. Eur Uro suppl,2008,7(3):151.
[70]Gao B, Yasui T, Itoh Y, et al. Association of osteopontin gene haplotypes with nephrolithiasis[J].Kidney international,2007,72(5):592-8.
[71]Xu AP, Bai J, Lu J, et al. Osteopontin gene polymorphism in association with systemic lupus erythematosus in Chinese patients[J]. Chinese medical journal, 2007,120(23):2124-8.
[72]Scheid C, Koul H, Hill WA, et al. Oxalate toxicity in LLC-PK1 cells:role of free radicals[J]. Kidney international,1996,49(2):413-9.
[73]Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease[J]. Kidney international,1994,46(3):847-54.
[74]Hackett RL, Shevock PN, Khan SR. Cell injury associated calcium oxalate crystalluria[J]. The Journal of urology,1990,144(6):1535-8.
[75]Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease[J]. Investigative urology,1978,15(6):442-8.
[76]Lee SJ, Lee SY, Jeon HS, et al.Vascular endothelial growth factor gene polymor-phisms and risk of primary lung cancer[J].Cancer epidemiology, biomarkers & prevention,2005,14(3):571-5.
[77]Chen WC, Chen HY, Wu HC, et al. Vascular endothelial growth factor gene polymorphism is associated with calcium oxalate stone disease[J]. Urological research, 2003,31(3):218-22.
[78]Beaudreuil J, Taboulet J, Orcel P, et al.Calcitonin receptor mRNA in mononuclear leucocytes from postmenopausal women:decrease during osteoporosis and link to bone markers with specific isoform involvement[J]. Bone,2000,27(1):161-8.
[79]Nakamura M, Morimoto S, Zhang Z,et al.Calcitonin receptor gene polymorphism in Japanese women:correlation with body mass and bone mineral density[J]. Calcified tissue international,2001,68(4):211-5.
[80]章振林,孟迅吾,周学瀛,等.北京地区汉族妇女维生素D受体基因和降钙素受体基因多态性与骨密度的关系[J].中华内分泌代谢杂志,2002,18(2)：90-94.
[81]Chen WC, Wu HC, Lu HF, et al.Calcitonin receptor gene polymorphism:a possible genetic marker for patients with calcium oxalate stones[J].European urology, 2001,39(6):716-9.
[82]Kitching AR, Holdsworth SR, Ploplis VA, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis[J]. The Journal of experimental medicine,1997,185(5):963-8.
[83]Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria[J].kidney international,1995,47(6):1546-57.
[84]Du Toit PJ, Van Aswegen CH, Steinmann CM, et al. Does urokinase play a role in renal stone formation?[J]. Medical hypotheses,1997,49(1):57-9.
[85]Van Aswegen CH, Du Plessis DJ. Pathogenesis of kidney stones[J]. Medical hypotheses,1991,36(4):368-70.
[86]Du Toit PJ, Van Aswegen CH, Nel JA, et al. In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity[J].Urological research,1995,23(5):335-8.
[87]Dan Aswegen CH, Dirksen van Sckalckwyk JC, du Toit PJ, et al.The effect of calcium and magnesium ions on urinary urokinase and sialidase activity[J]. Urological research,1992,20(1):41-4.
[88]Tripputi P, Blasi F, Verde P, et al.Human urokinase gene is located on the long arm of chromosome 10[J]. Proceedings of the National Academy of Sciences of the United States of America,1985,82(13):4448-52.
[89]Tsai MH,Chen WC,Chen HY,et al.Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer[J] Journal of clinical laboratory analysis,2004,18(5): 276-9.
[90]Ozturk M,Kordan Y,Cangul H,et al. Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children[J]. International urology and nephrology,2008,40(3):563-8.
[91]Spurr NK. Genetics of calcium-sensing--regulation of calcium levels in the body [J].Current opinion in pharmacology,2003,3(3):291-4.
[92]Heath HI, Odelberg S, Jackson CE, et al. Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalci uric hypercalcemia suggest receptor functional domains[J]. The Journal of clinical endocrinology and metabolism,1996,81 (4):1312-7.
[93]杨奕,王少刚,叶章群,等.钙敏感受体基因第7外显子单核甘酸多态性与特发性高钙尿症的关系[J].中华实验外科杂志,2006,23(5)：588-590.
[94]Vezzoli G, Tanini A, Ferrucci L, et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients[J]. Journal of the American Society of Nephrology,2002,13(10):2517-23.
[95]Chen WC, Lu HF, Chen HY, et al. Arginine form of p21 gene codon 31 is less prominent in patients with calcium oxalate stone[J]. Urological research,2001, 29(2):94-7.
[96]Lai KC, Lin WY, Man KM, et al.Association of interleukin-18 gene polymorphis ms with calcium oxalate kidney stone disease[J]. Scandinavian journal of urology and nephrology,2010,44(1):20-6.
[97]Aksoy H, Aksoy Y, Ozturk N, et al. Fetuin-A Gene Polymorphism in Patients With Calcium Oxalate Stone Disease[J]. Urology,2009,75(4):928-32.
[98]Onaran M, Yilmaz A, Sen I, et al. A HindⅢ polymorphism of fibronectin gene is associated with nephrolithiasis[J]. Urology,2009,74(5):1004-7.
[99]Mittal RD, Bid HK, Manchanda PK. Genotype and haplotype determination of IL1B (g.-511C>T and g.+3954C＞T) and (IL1RN) in pediatric nephrolithiasis[J]. Clinica chimica acta,2007,379(1-2):42-7.
[100]Mittal RD, Bid HK, Manchanda PK, et al. Association of interleukin-1beta gene and receptor antagonist polymorphisms with calcium oxalate urolithiasis[J]. Journal of endourology/Endourological Society,2007,21(12):1565-70.
[101]Tugcu V, Ozbek E, Aras B, et al. Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis[J]. Urological research,2007,35(5):219-24.
[102]Huang SH, Chen RH, Wan L, et al. TAP 2 gene Msp-I polymorphism might be associated with calcium oxalate stone disease[J]. Urologia internationalis,2005, 75(3):264-8.
[103]Tsai FJ, Wu HC, Chen HY, et al. Association of E-cadherin gene 3'-UTR C/T polymorphism with calcium oxalate stone disease[J].Urologia internationalis, 2003,70(4):278-81.
[104]Chen WC, Wu HC, Lin WC, et al. The association of androgen-and oestrogen-receptor gene polymorphisms with urolithiasis in men[J]. BJU international,2001, 88(4):432-6.
[2]TISELIUS HGEpidemiology and medical management of stone disease[J]. BJU Int,2003,91(8):758-767.
[3]孙伟桂,丁智仁,张峻,等.广西的区尿石症患者年龄分布曲线特征及临床意义[J].中华泌尿外科杂志,2001,22(2)：100-102.
[4]欧阳健明.草酸钙结石研究中的化学基础[J].化学通报,2002(5)：326-332.
[5]Uribarri J, Oh MS, Carroll HJ. The first kidney stone[J]. Annals of internal medicine,1989,111(12):1006-9.
[6]Coe FL, Parks JH, Asplin JR.The pathogenesis and treatment of kidney stones [J]. The New England journal of medicine,1992,327(16):1141-52.
[7]陈孝平,主编.外科学[M].北京：人民卫生出版社,2005.858.
[8]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.54-55.
[9]Kumar V, Lieske JC. Protein regulation of intrarenal crystallization[J]. Current Opinionin nephrology and hypertension,2006,15(4):374-80.
[10]De Yoreo JJ, Qiu SR, Hoyer JR.Molecular modulation of calcium oxalate crystal lization[J].American journal of physiology.Renal physiology,2006,291 (6):1123-31.
[11]Filmus J, Selleck SB.Glypicans:proteoglycans with a surprise[J]. The Journal of clinical investigation,2001,108(4):497-501.
[12]Iozzo RV.Heparan sulfate proteoglycans:intricate molecules with intriguing functions[J]. The Journal of clinical investigation,2001,108(2):165-7.
[13]Groffen AJ, Veerkamp JH, Monnens LA, et al.Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane[J]. Nephrology, dialysis, transplantation,1999,14(9):2119-29.
[14]Iwata H, Terado T, Kin M, et al.Isolation of urinary heparan sulfate and chondroitin sulfate and their inhibitory activity of calcium oxalate crystal growth[J]. The Japanese Journal of Urology,1991,82(3):405-11.
[15]Iida S, Miyajima J, Suzuki K, et al. Expression of heparan sulfate proteoglycan mRNA in rat kidneys during calcium oxalate nephrolithiasis[J]. Urological research, 1997,25(5):361-4.
[16]Iida S, Inoue M, Yoshii S, et al. Molecular detection of heparan sulfate proteogly can mRNA in rat kidney during calcium oxalate nephrolithiasis[J] Journal of the American Society of Nephrology,1999,10 Suppl14:S412-6.
[17]Eguchi Y, Inoue M, Iida S, et al. Heparan sulfate (HS)/heparan sulfate proteogly can (HSPG) and bikunin are up-regulated during calcium oxalate nephrolithiasis in rat kidney[J]. The Kurume medical journal,2002,49(3):99-107.
[18]Matsuo M. Increased expression of heparan sulfate proteoglycan on the cultured renal epithelial cells during oxalate exposure[J]. The Kurume medical journal,2008, 55(1-2):19-28.
[19]Chikama S, Iida S, Inoue M, et al.Role of heparan sulfate proteoglycan (syndecan-1) on the renal epithelial cells during calcium oxalate monohydrate crystal attachment[J]. The Kurume medical journal,2002,49(4):201-10.
[20]Angell AH, Resnick MI.Surface interaction between glycosaminoglycans and calcium oxalate[J]. The Journal of urology,1989,141(5):1255-8.
[21]Hansen PM, Chowdhury T, Deckert T,et al.Genetic variation of the heparin sulfate proteoglycan gene (perlecan gene). Association with urinary albumin excretion in IDDM patients[J]. Diabetes,1997,46(10):1658-9.
[22]Liu L, Xiang K, Zheng T, et al.The heparan sulfate proteoglycan gene polymor phism:association with type 2 diabetic nephropathy in Chinese[J]. Molecular and cellular biochemistry,2003,245(1-2):121-6.
[23]Onaran M, Yilmaz A, Sen I, et al.Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis[J].Urological research,2009,37(l):47-50.
[24]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.301.
[25]叶章群,邓耀良,董诚主编.泌尿系结石[M].北京：人民卫生出版社,2003.215.
[26]Winter P, Schoeneich G, Ganter K, et al.Extracorporeal shock wave lithotripsy and glycosaminoglycans in urine[J].International urology and nephrology,1998, 30(2):113-21.
[27]Garside RF. Bimodality and the nature of depression[J].The British journal of psychiatry:the journal of mental science,1981,139:168-9.
[28]Khan SR. Role of renal epithelial cells in the initiation of calcium oxalate stones [J].Nephron. Experimental nephrology,2004,98(2):55-60.
[29]Khan SR, Kok DJ. Modulators of urinary stone formation[J]. Frontiers in bio science,2004,9:1450-82.
[30]Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans[J]. Annual review of biomedical engineering,2006,8:181-231.
[31]Borges FT, Michelacci YM, Aguiar JA, et al.Characterization of glycosaminogly cans in tubular epithelial cells:calcium oxalate and oxalate ions effects[J]. Kidney international,2005,68(4):1630-42.
[32]Rosenmann H, Meiner Z, Kahana E, et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease[J]. American journal of medical genetics,2004,128B(1):123-5.
[33]Iivonen S, Helisalmi S, Mannermaa A, et al. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology[J]. Neuroscience letters,2003,352(2):146-50.
[34]Datta MW, Hernandez AM, Schlicht MJ, et al. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway [J].Molecular cancer,2006,5:9.
[35]李大伟,焦伟,王铁柳,等.硫酸乙酰肝素蛋白多糖基因多态性与草酸钙结石易感性的关系.山东大学学报.2010,48(1)：89-94.
[36]Minamitani K, Takahashi Y, Minagawa M, et al. Difference in height associated with a translation start site polymorphism in the vitamin D receptor gene[J]. Pediatric research,1998,44(5):628-32.
[37]Ferrari S, Rizzoli R, Manen D, et al.Vitamin D receptor gene start codon polymer phisms(Fokl) and bone mineral density:interaction with age, dietary calcium, and 3'-end region polymorphisms[J].Journal of bone and mineral research,1998,13(6): 925-30.
[38]董砚虎,翟木绪,李长贵,等.糖尿病维生素D受体基因多态性与骨密度相 关性研究[J].中华内分泌代谢杂志,2002,18(2)：111-115.
[39]易广才,邵振堂,阮滨.维生素D受体基因内切酶位点多态与孕妇骨密度和补钙的关系[J].中国优生与遗传杂志,2002,10(2)：111-115.
[40]Ozkaya O, Soylemezoglu O, Misirlioglu M, et al. Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children[J].European urology,2003,44(1):150-4.
[41]Nishijima S, Sugaya K, Naito A, et al. Association of vitamin D receptor gene polymorphism with urolithiasis[J].The Journal of urology,2002,167(5):2188-91.
[42]Gunes S, Bilen CY, Kara N, et al. Vitamin D receptor gene polymorphisms in patients with urolithiasis[J].Urological research,2006,34(1):47-52.
[43]Jackman SV, Kibel AS, Ovuworie CA, et al. Familial calcium stone disease:TaqI polymorphism and the vitamin D receptor[J] Journal of endourology,1999,13(4): 313-6.
[44]Heilberg IP, Teixeira SH, Martini LA, et al.Vitamin D receptor gene polymorphism and bone mineral density in hypercalciuric calcium-stone-forming patients[J].Nephron,2002,90(1):51-7.
[45]Bid HK,Chaudhary H, Mittal RD.Association of vitamin-D and calcitonin receptor gene polymorphism in paediatric nephrolithiasis[J]. Pediatric nephrology (Berlin, Germany),2005,20(6):773-6.
[46]Chen WC, Chen HY, Lu HF, et al. Association of the vitamin D receptor gene start codon Fok I polymorphism with calcium oxalate stone disease[J].BJU international,2001,87(3):168-71.
[47]胡少群,刘继红,王少刚,等.维生素D受体基因多态性与草酸钙尿结石的关系[J].中华泌尿外科杂志,2004,25(3)：155-157.
[48]王勤章,钱彪,丁国富,等.新疆南部维吾尔族泌尿系结石患者维生素D受体基因多态性的研究[J].实用医学杂志,2009,25(17)：2805-2807.
[49]梁颖,刘忠厚.遗传决定骨量[J].中国骨质疏松杂志,2005,11(2)：269-272.
[50]苗懿德,刘杰,何培英,等.老年男性维生素D受体基因多态性与骨转换指 标及1,25(OH)2D3的关系[J].中国临床康复,2004,8(33)：7469-7471.
[51]Urivetzky M, Anna PS, Smith AD. Plasma osteocalcin levels in stone disease. A potential aid in the differential diagnosis of calcium nephrolithiasis[J]. The Journal of urology,1988,139(1):12-4.
[52]Yasui T, Fujita K, Sasaki S, et al. Expression of bone matrix proteins in urolithiasis model rats[J].Urological research,1999,27(4):255-61.
[53]McKee MD, Nanci A, Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi[J]. Journal of bone and mineral research,1995,10(12):1913-29.
[54]Worcester EM, Sebastian JL, Hiatt JG, et al. The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin[J] Calcified tissue international,1993,53(4):242-8.
[55]Dohi Y, Iki M, Ohgushi H, et al. A novel polymorphism in the promoter region for the human osteocalcin gene:the possibility of a correlation with bone mineral density in postmenopausal Japanese women[J] Journal of bone and mineral research,1998,13(10):1633-9.
[56]Celeste AJ, Rosen V, Buecker JL, et al. Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones[J].The EMBO journal,1986,5 (8): 1885-90.
[57]Raymond MH, Schutte BC, Torner JC, et al. Osteocalcin:genetic and physical mapping of the human gene BGLAP and its potential role in postmenopausal osteoporosis[J].Genomics,1999,60(2):210-7.
[58]Morrison N, Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter[J]. Journal of bone and mineral research,1993,8(8):969-75.
[59]Mo XY, Cao CK, Xu FH, et al. Lack of association between the HindⅢ RFLP of the osteocalcin (BGP) gene and bone mineral density (BMD) in healthy pre-and postmenopausal Chinese women[J]. Journal of bone and mineral metabolism,2004, 22(3):264-9.
[60]吴青,张红红,刘建伟,等.汉族人骨钙素基因多态性和骨质疏松的关系[J].中国临床康复,2004,8(30)：6806-6807.
[61]Chen WC, Chen HY, Wu JY, et al. Osteocalcin gene Hind Ⅲ polymorphism is not correlated with calcium oxalate stone disease[J]. Urological research,2001,29(2): 98-101.
[62]Tawada T, Fujita K, Sakakura T, et al. Distribution of osteopontin and calprotectin as matrix protein in calcium-containing stone[J]. Urological research,1999,27(4): 238-42.
[63]Shiraga H, Min W, VanDusen WJ, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin:another member of the aspartic acid-rich protein superfamily[J]. Proceedings of the National Academy of Sciences of the United States of America,1992,89(1):426-30.
[64]常连胜,冯陶,郭应禄,等.结石病人尿骨桥蛋白测定的临床意义.中华泌尿外科杂志.2000,21(12)：709-711.
[65]Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals [J].Kidney international,2001,60(1):77-82.
[66]Butler WT. The nature and significance of osteopontin[J]. Connective tissue research,1989,23(2-3):123-36.
[67]Gao B, Yasui T, Okada A, et al. A polymorphism of the osteopontin gene is related to urinary calcium stones[J].The Journal of urology,2005,174(l):1472-6.
[68]Kikuchi K, Tanaka A, Miyakawa H, et al.Eta-1/osteopontin genetic polymor phism and primary biliary cirrhosis[J].Hepatology research,2003,26(2):87-90.
[69]Lee M.K,Kim T.H,Lee S.Y,et al. ETA-1/OSTEOPONTIN GENETIC POLYMORPHISIMS ASSOCIATED WITH UROLITHIASIS IN KOREA[J]. Eur Uro suppl,2008,7(3):151.
[70]Gao B, Yasui T, Itoh Y, et al. Association of osteopontin gene haplotypes with nephrolithiasis[J].Kidney international,2007,72(5):592-8.
[71]Xu AP, Bai J, Lu J, et al. Osteopontin gene polymorphism in association with systemic lupus erythematosus in Chinese patients[J]. Chinese medical journal, 2007,120(23):2124-8.
[72]Scheid C, Koul H, Hill WA, et al. Oxalate toxicity in LLC-PK1 cells:role of free radicals[J]. Kidney international,1996,49(2):413-9.
[73]Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease[J]. Kidney international,1994,46(3):847-54.
[74]Hackett RL, Shevock PN, Khan SR. Cell injury associated calcium oxalate crystalluria[J]. The Journal of urology,1990,144(6):1535-8.
[75]Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease[J]. Investigative urology,1978,15(6):442-8.
[76]Lee SJ, Lee SY, Jeon HS, et al.Vascular endothelial growth factor gene polymor-phisms and risk of primary lung cancer[J].Cancer epidemiology, biomarkers & prevention,2005,14(3):571-5.
[77]Chen WC, Chen HY, Wu HC, et al. Vascular endothelial growth factor gene polymorphism is associated with calcium oxalate stone disease[J]. Urological research, 2003,31(3):218-22.
[78]Beaudreuil J, Taboulet J, Orcel P, et al.Calcitonin receptor mRNA in mononuclear leucocytes from postmenopausal women:decrease during osteoporosis and link to bone markers with specific isoform involvement[J]. Bone,2000,27(1):161-8.
[79]Nakamura M, Morimoto S, Zhang Z,et al.Calcitonin receptor gene polymorphism in Japanese women:correlation with body mass and bone mineral density[J]. Calcified tissue international,2001,68(4):211-5.
[80]章振林,孟迅吾,周学瀛,等.北京地区汉族妇女维生素D受体基因和降钙素受体基因多态性与骨密度的关系[J].中华内分泌代谢杂志,2002,18(2)：90-94.
[81]Chen WC, Wu HC, Lu HF, et al.Calcitonin receptor gene polymorphism:a possible genetic marker for patients with calcium oxalate stones[J].European urology, 2001,39(6):716-9.
[82]Kitching AR, Holdsworth SR, Ploplis VA, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis[J]. The Journal of experimental medicine,1997,185(5):963-8.
[83]Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria[J].kidney international,1995,47(6):1546-57.
[84]Du Toit PJ, Van Aswegen CH, Steinmann CM, et al. Does urokinase play a role in renal stone formation?[J]. Medical hypotheses,1997,49(1):57-9.
[85]Van Aswegen CH, Du Plessis DJ. Pathogenesis of kidney stones[J]. Medical hypotheses,1991,36(4):368-70.
[86]Du Toit PJ, Van Aswegen CH, Nel JA, et al. In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity[J].Urological research,1995,23(5):335-8.
[87]Dan Aswegen CH, Dirksen van Sckalckwyk JC, du Toit PJ, et al.The effect of calcium and magnesium ions on urinary urokinase and sialidase activity[J]. Urological research,1992,20(1):41-4.
[88]Tripputi P, Blasi F, Verde P, et al.Human urokinase gene is located on the long arm of chromosome 10[J]. Proceedings of the National Academy of Sciences of the United States of America,1985,82(13):4448-52.
[89]Tsai MH,Chen WC,Chen HY,et al.Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer[J] Journal of clinical laboratory analysis,2004,18(5): 276-9.
[90]Ozturk M,Kordan Y,Cangul H,et al. Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children[J]. International urology and nephrology,2008,40(3):563-8.
[91]Spurr NK. Genetics of calcium-sensing--regulation of calcium levels in the body [J].Current opinion in pharmacology,2003,3(3):291-4.
[92]Heath HI, Odelberg S, Jackson CE, et al. Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalci uric hypercalcemia suggest receptor functional domains[J]. The Journal of clinical endocrinology and metabolism,1996,81 (4):1312-7.
[93]杨奕,王少刚,叶章群,等.钙敏感受体基因第7外显子单核甘酸多态性与特发性高钙尿症的关系[J].中华实验外科杂志,2006,23(5)：588-590.
[94]Vezzoli G, Tanini A, Ferrucci L, et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients[J]. Journal of the American Society of Nephrology,2002,13(10):2517-23.
[95]Chen WC, Lu HF, Chen HY, et al. Arginine form of p21 gene codon 31 is less prominent in patients with calcium oxalate stone[J]. Urological research,2001, 29(2):94-7.
[96]Lai KC, Lin WY, Man KM, et al.Association of interleukin-18 gene polymorphis ms with calcium oxalate kidney stone disease[J]. Scandinavian journal of urology and nephrology,2010,44(1):20-6.
[97]Aksoy H, Aksoy Y, Ozturk N, et al. Fetuin-A Gene Polymorphism in Patients With Calcium Oxalate Stone Disease[J]. Urology,2009,75(4):928-32.
[98]Onaran M, Yilmaz A, Sen I, et al. A HindⅢ polymorphism of fibronectin gene is associated with nephrolithiasis[J]. Urology,2009,74(5):1004-7.
[99]Mittal RD, Bid HK, Manchanda PK. Genotype and haplotype determination of IL1B (g.-511C>T and g.+3954C＞T) and (IL1RN) in pediatric nephrolithiasis[J]. Clinica chimica acta,2007,379(1-2):42-7.
[100]Mittal RD, Bid HK, Manchanda PK, et al. Association of interleukin-1beta gene and receptor antagonist polymorphisms with calcium oxalate urolithiasis[J]. Journal of endourology/Endourological Society,2007,21(12):1565-70.
[101]Tugcu V, Ozbek E, Aras B, et al. Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis[J]. Urological research,2007,35(5):219-24.
[102]Huang SH, Chen RH, Wan L, et al. TAP 2 gene Msp-I polymorphism might be associated with calcium oxalate stone disease[J]. Urologia internationalis,2005, 75(3):264-8.
[103]Tsai FJ, Wu HC, Chen HY, et al. Association of E-cadherin gene 3'-UTR C/T polymorphism with calcium oxalate stone disease[J].Urologia internationalis, 2003,70(4):278-81.
[104]Chen WC, Wu HC, Lin WC, et al. The association of androgen-and oestrogen-receptor gene polymorphisms with urolithiasis in men[J]. BJU international,2001, 88(4):432-6.